The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Cancer and the tumor microenvironment: a review of an essential relationship
Open accessAbstract
PurposeThe role of the microenvironment during the initiation and progression of carcinogenesis is now realized to be of critical importance, both for enhanced understanding of fundamental cancer biology, as well as exploiting this source of relatively new knowledge for improved molecular diagnostics and therapeutics.MethodsThis review focuses on: (1) the approaches of preparing and analyzing secreted proteins, (2) the contribution of tumor microenvironment elements in cancer, and (3) the potential molecular targets for cancer therapy.ResultsThe microenvironment of a tumor is an integral part of its physiology, structure, and function. It is an essential aspect of the tumor proper, since it supplies a nurturing environment for the malignant process. A fundamental deranged relationship between tumor and stromal cells is essential for tumor cell growth, progression, and development of life threatening metastasis. Improved understanding of this interaction may provide new and valuable clinical targets for cancer management, as well as risk assessment and prevention. Non-malignant cells and secreted proteins from tumor and stromal cells are active participants in cancer progression.ConclusionsMonitoring the change in the tumor microenvironment via molecular and cellular profiles as tumor progresses would be vital for identifying cell or protein targets for cancer prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Electrospray Ionization for Mass Spectrometry of Large Biomolecules
Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989) · Science · doi:10.1126/science.2675315 · Cited by 7,634
Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., & Mann, M. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200025-mcp200 · Cited by 5,574 · cited 2×
“Described technologies such as isotope-coded aYnity tagging (ICAT) [31, 32] and stable isotope labeling with amino acids in cell culture (SILAC) [33, 34] can be combined with mass spectrometry approaches to produce”
BackgroundQuantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683 · cited 2×
“Described technologies such as isotope-coded aYnity tagging (ICAT) [31, 32] and stable isotope labeling with amino acids in cell culture (SILAC) [33, 34] can be combined with mass spectrometry approaches to produce”
BackgroundKalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STATs phosphorylation, which is required for transcriptional activity, is regulated by kinases, phosphatases and binding proteins, which are good targets for cancer therapy [ 76 ].”
BackgroundMendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1477 · Cited by 1,765
Weinberg, R. A., & Weinberg, R. A. (2006) · W.W. Norton eBooks · doi:10.1201/9780203852569 · Cited by 1,751
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Integrin signalling during tumour progression
Guo, W., & Giancotti, F. G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1490 · Cited by 1,471
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Etzioni, R., Urban, N., Ramsey, S., McIntosh, M., Schwartz, S., Reid, B., Radich, J., Anderson, G., & Hartwell, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1041 · Cited by 1,155
The tumour microenvironment as a target for chemoprevention
Albini, A., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2067 · Cited by 823
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
The two faces of transforming growth factor β in carcinogenesis
Roberts, A. B., & Wakefield, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633291100 · Cited by 747
Differential exoprotease activities confer tumor-specific serum peptidome patterns
Villanueva, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26022 · Cited by 741
Infections as a major preventable cause of human cancer
Kuper, H., Adami, H. ‐., & Trichopoulos, D. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00742.x · Cited by 740
Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739
Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1
Noë, V., Fingleton, B., Jacobs, K., Crawford, H. C., Vermeulen, S., Steelant, W., Bruyneel, E., Matrisian, L. M., & Mareel, M. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.1.111 · Cited by 695
Altered wound healing in mice lacking a functional osteopontin gene (spp1).
Liaw, L., Birk, D. E., Ballas, C. B., Whitsitt, J. S., Davidson, J. M., & Hogan, B. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2131 · Cited by 663
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Joyce, J. A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F.-Y., Greenbaum, D. C., Hager, J. H., Bogyo, M., & Hanahan, D. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00111-4 · Cited by 645
Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36505 · Cited by 586
Therapeutic targeting of the tumor microenvironment
Joyce, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.024 · Cited by 582
Integrins: roles in cancer development and as treatment targets
Jin, H., & Varner, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601576 · Cited by 574
Hamano, Y., Zeisberg, M., Sugimoto, H., Lively, J. C., Maeshima, Y., Yang, C., Hynes, R. O., Werb, Z., Sudhakar, A., & Kalluri, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00133-8 · Cited by 559
Alterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539
Transforming growth factor production by chemically transformed cells.
Moses, H. L., Branum, E. L., Proper, J. A., & Robinson, R. A. (1981) · PubMed · Cited by 497
Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach
Grønborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R., Reddy, R., Sato, N., Molina, H., Jensen, O. N., Hruban, R. H., Goggins, M. G., et al. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500178-mcp200 · Cited by 482
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Comparison of protein precipitation methods for sample preparation prior to proteomic analysis
Jiang, L., He, L., & Fountoulakis, M. (2004) · Journal of Chromatography A · doi:10.1016/j.chroma.2003.10.029 · Cited by 467
PDGF receptors as cancer drug targets
Pietras, K., Sjöblom, T., Rubin, K., Heldin, C.-H., & Östman, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00089-8 · Cited by 465
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460
Precision proteomics: The case for high resolution and high mass accuracy
Mann, M., & Kelleher, N. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800788105 · Cited by 450 · cited 2×
“unlikely to be directly associated with the disease [27].”
BackgroundGraff, J. R., McNulty, A. M., Hanna, K. R., Konicek, B. W., Lynch, R. L., Bailey, S. N., Banks, C., Capen, A., Goode, R., Lewis, J. E., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0071 · Cited by 442
Scott, A. M., Wiseman, G., Welt, S., Adjei, A. A., Lee, F.-T., Hopkins, W., Divgi, C. R., Hanson, L. J., Mitchell, P., Gansen, D. N., et al. (2003) · PubMed · Cited by 438
Rittling, S. R., Matsumoto, H. N., Mckee, M. D., Nanci, A., An, X.-R., Novick, K. E., Kowalski, A. J., Noda, M., & Denhardt, D. T. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.7.1101 · Cited by 438
Central obesity and breast cancer risk: a systematic review
Harvie, M., Hooper, L., & Howell, A. H. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00108.x · Cited by 391
Stat3 regulates genes common to both wound healing and cancer
Dauer, D. J., Ferraro, B., Song, L., Yu, B., Mora, L., Buettner, R., Enkemann, S., Jove, R., & Haura, E. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208469 · Cited by 380
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
Gutheil, J. C., Campbell, T. N., Pierce, P. R., Watkins, J. D., Huse, W. D., Bodkin, D., & Cheresh, D. A. (2000) · PubMed · Cited by 369
García Rodríguez, L. A., & Huerta-Alvarez, C. (2001) · Epidemiology · doi:10.1097/00001648-200101000-00015 · Cited by 359
Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?
Diamandis, E. P. (2003) · Clinical Chemistry · doi:10.1373/49.8.1272 · Cited by 324
Nakajima, M., Welch, D. R., Belloni, P., & Nicolson, G. L. (1987) · PubMed · Cited by 311
Metalloproteinases and their inhibitors in tumor angiogenesis
Handsley, M. M., & Edwards, D. R. (2005) · International Journal of Cancer · doi:10.1002/ijc.20945 · Cited by 307
Gygi, S. P., Rist, B., Griffin, T. J., Eng, J., & Aebersold, R. (2002) · Journal of Proteome Research · doi:10.1021/pr015509n · Cited by 307
NF‐κB and cancer: Mechanisms and targets
Karin, M. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20217 · Cited by 298
The metastasis gene osteopontin: a candidate target for cancer therapy
Weber, G. F. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00037-3 · Cited by 286
The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
Devy, L., Blacher, S., Grignet-Debrus, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0552com · Cited by 280
Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
Rudland, P. S., Platt-Higgins, A. M., El‐Tanani, M., Rudland, S. D. S., Barraclough, R., Winstanley, J. H. R., Howitt, R., & West, C. R. (2002) · PubMed · Cited by 276
Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer
Li, Y., Hively, W. P., & Varmus, H. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203273 · Cited by 255
Burke, P. A., DeNardo, S. J., Miers, L. A., Lamborn, K. R., Matzku, S., & DeNardo, G. L. (2002) · PubMed · Cited by 253
P700: the primary electron donor of photosystem I
Webber, A. N., & Lubitz, W. (2001) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(01)00198-0 · Cited by 251
Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties
Matarrese, P., Fusco, O., Tinari, N., Natoli, C., Liu, F.-T., Semeraro, M. L., Malorni, W., & Iacobelli, S. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000215)85:4<545::aid-ijc17>3.0.co;2-n · Cited by 244
Celecoxib: A Specific COX-2 Inhibitor with Anticancer Properties
Koki, A. T., & Masferrer, J. L. (2002) · Cancer Control · doi:10.1177/107327480200902s04 · Cited by 233
Proteases, Extracellular Matrix, and Cancer
DeClerck, Y. A., Mercurio, A. M., Stack, M. S., Chapman, H. A., Zutter, M. M., Muschel, R. J., Raz, A., Matrisian, L. M., Sloane, B. F., Noel, A., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63200-2 · Cited by 232
Comprehensive Proteomic Analysis of Human Pancreatic Juice
Grønborg, M., Bunkenborg, J., Kristiansen, T. Z., Jensen, O. N., Yeo, C. J., Hruban, R. H., Maitra, A., Goggins, M. G., & Pandey, A. (2004) · Journal of Proteome Research · doi:10.1021/pr0499085 · Cited by 199
Combretastatin A4 phosphate: background and current clinical status
Young, S. L., & Chaplin, D. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1171 · Cited by 192
Inohara, H., Honjo, Y., Yoshii, T., Akahani, S., Yoshida, J.-I., Hattori, K., Okamoto, S., Sawada, T., Raz, A., & Kubo, T. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990601)85:11<2475::aid-cncr25>3.0.co;2-1 · Cited by 187
Drug resistance and the microenvironment: nature and nurture
Morin, P. J. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00059-1 · Cited by 182
The regulation and role of osteopontin in malignant transformation and cancer
ELTANANI, M., CAMPBELL, F., KURISETTY, V, JIN, D., MCCANN, M., & RUDLAND, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.09.010 · Cited by 174
Toward a better analysis of secreted proteins: the example of the myeloid cells secretome
Chevallet, M., Diemer, H., Van Dorssealer, A., Villiers, C., & Rabilloud, T. (2007) · PROTEOMICS · doi:10.1002/pmic.200601024 · Cited by 172
Bertl, E., Bartsch, H., & Gerhäuser, C. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0324 · Cited by 169
Joyce, J. A., Freeman, C., Meyer-Morse, N., Parish, C. R., & Hanahan, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208602 · Cited by 163
Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells.
Honjo, Y., Nangia‐Makker, P., Inohara, H., & Raz, A. (2001) · PubMed · Cited by 163
The Role of Osteopontin in Breast Cancer: Clinical and Experimental Studies
Tuck, A. B., & Chambers, A. F. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1014734930781 · Cited by 160
Mangala, L. S., Fok, J. Y., Zorrilla, I. R., Verma, A., & Mehta, K. (2006) · Oncogene · doi:10.1038/sj.onc.1210035 · Cited by 159
A Proteomic Analysis of Human Bile
Kristiansen, T. Z., Bunkenborg, J., Gronborg, M., Molina, H., Thuluvath, P. J., Argani, P., Goggins, M. G., Maitra, A., & Pandey, A. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400015-mcp200 · Cited by 159
Matrilysin [MMP-7] Expression Selects for Cells with Reduced Sensitivity to Apoptosis
Fingleton, B., Vargo-Gogola, T., Crawford, H. C., & Matrisian, L. M. (2001) · Neoplasia · doi:10.1038/sj.neo.7900190 · Cited by 158
Quantitative Proteomic Analysis of Proteins Released by Neoplastic Prostate Epithelium
Martin, D. B., Gifford, D. R., Wright, M. E., Keller, A., Yi, E. C., Goodlett, D. R., Aebersold, R. H., & Nelson, P. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2062 · Cited by 140
Tuck, A. B., Elliott, B. E., Hota, C., Tremblay, E., & Chambers, A. F. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20000901)78:3<465::aid-jcb11>3.0.co;2-c · Cited by 137
Manley, P. W., Bold, G., Brüggen, J., Fendrich, G., Furet, P., Mestan, J., Schnell, C., Stolz, B., Meyer, T., Meyhack, B., et al. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.010 · Cited by 136
Tuck, A. B., Hota, C., Wilson, S. M., & Chambers, A. F. (2003) · Oncogene · doi:10.1038/sj.onc.1206209 · Cited by 128
Mbeunkui, F., Metge, B. J., Shevde, L. A., & Pannell, L. K. (2007) · Journal of Proteome Research · doi:10.1021/pr060629m · Cited by 117
Self-citationNew insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent
Mooberry, S. L. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00004 · Cited by 106
Mbeunkui, F., Fodstad, Ø., & Pannell, L. K. (2006) · Journal of Proteome Research · doi:10.1021/pr050375p · Cited by 98
Self-citationGerner, C., Vejda, S., Gelbmann, D., Bayer, E., Gotzmann, J., Schulte‐Hermann, R., & Mikulits, W. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200026-mcp200 · Cited by 89
Volmer, M. W., Stühler, K., Zapatka, M., Schoeneck, A., Klein‐Scory, S., Schmiegel, W., Meyer, H. E., & Schwarte‐Waldhoff, I. (2005) · PROTEOMICS · doi:10.1002/pmic.200401188 · Cited by 88
Amanchy, R., Kalume, D. E., & Pandey, A. (2005) · Science s STKE · doi:10.1126/stke.2672005pl2 · Cited by 87
Proteomic identification of the wt-p53-regulated tumor cell secretome
Khwaja, F. W., Svoboda, P., Reed, M. S., Pohl, J., Pyrzyńska, B., & Meir, E. G. V. (2006) · Oncogene · doi:10.1038/sj.onc.1209969 · Cited by 77
Mi, Z., Oliver, T., Guo, H., Gao, C., & Kuo, P. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4066 · Cited by 60
Pardo, M., García, Á. G., Antrobus, R., Blanco, M. J., Dwek, R. A., & Zitzmann, N. (2007) · Journal of Proteome Research · doi:10.1021/pr070021t · Cited by 58
Neovastat—a novel antiangiogenic drug for cancer therapy
Gingras, D., Boivin, D., Deckers, C., Gendron, S. P., Barthomeuf, C., & Béliveau, R. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200302000-00001 · Cited by 57
A Proteomic Approach to the Identification of Lung Cancer Markers
Hanash, S., Brichory, F., & Beer, D. G. (2001) · Disease Markers · doi:10.1155/2001/657605 · Cited by 55
Thalidomide in solid tumours: the resurrection of an old drug
Sleijfer, S., Kruit, W. H. J., & Stoter, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.023 · Cited by 44
Volmer, M. W., Radacz, Y., Hahn, S. A., Klein‐Scory, S., Stühler, K., Zapatka, M., Schmiegel, W., Meyer, H. E., & Schwarte‐Waldhoff, I. (2004) · PROTEOMICS · doi:10.1002/pmic.200300703 · Cited by 43
Cited by
Cancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
Nath, S., & Devi, G. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.013 · Cited by 919
Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.01.066 · Cited by 849
Spatial profiling technologies illuminate the tumor microenvironment
Elhanani, O., Ben-Uri, R., & Keren, L. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.010 · Cited by 510
Metadata
- Authors
- Mbeunkui, F., & Johann, D. J.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2008-12-14
- Volume
- 63
- Issue
- 4
- Pages
- 571-582
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W1963525180
- Cited by
- 487
- References
- 96
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.